Table 1.

Subject demographics by continent of enrollment

	Australia (N = 17)	United States (N = 15)
Male	8 (47%)	3 (20%)
Caucasian/White	16 (94%)	15 (100%)
F508del homozygous	9 (53%)	8 (53%)
Age at bronchoscopy, mon	3.5 (±0.9)*	6 (±1.6)
Weight at bronchoscopy, kg	6.3 (±1)	7 (±1.3)
Lavage sequencing performed	16 (94%)	11 (73%)
Exclusively breast fed	6 (35%)	4 (27%)
Smoke exposure	2 (12%)	0
Prophylactic antibiotics	16 (94%)*	0
Treatment antibiotics	3 (18%)*	11 (73%)
No antibiotics	1 (6%)	4 (27%)

Subject demographics and characteristics by continent of enrollment, shown for all subjects (n = 32), presented as number and percentage or mean and standard deviation. Australian subjects were significantly younger than U.S. subjects at the time of bronchoscopy. All but one of the Australian subjects received prophylactic antibiotics, whereas no U.S. subjects was treated with antistaphylococcal prophylaxis (P < 0.01). U.S. subjects were more likely to receive treatment courses of antibiotics.

^*P ≤ 0.01 for difference between Australian and U.S. subjects.